Celularityの空売り状況は、投資家がCelularityの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Celularity (NASDAQ:CELU) 株価情報, 空売り情報

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

Amprius Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPX#NYSE">AMPX</a>) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.13) by 23.08 percent. The company reported quarterly sales of $7.855 million which beat the analyst consensus estimate of $4.215 million by 86.37 percent. This is a 180.74 percent increase over sales of $2.798 million the same period last year.

Earnings

Earnings Beats

News

AMPX

Amprius Technologies Q3 2024 GAAP EPS $(0.10) Beats $(0.13) Estimate, Sales $7.855M Beat $4.215M Estimate

Identiv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVE#NASDAQ">INVE</a>) sees Q4 sales of $6.000 million-6.300 million vs $5.95 million estimate.

Guidance

INVE

Identiv Sees Q4 Sales $6.000M-6.300M vs $5.95M Est

Fourth Quarter 2024 Outlook
For the fourth quarter 2024, the Company expects:
<ul>
<li>Revenue growth on a constant currency basis in the range of 10.3%-13.3%. This represents revenue in the range of $375-$385 million, assuming FX rates remain relatively stable with the end of Q3.&nbsp;</li>
<li>Adjusted EBITDA in the range of $9-$14 million, representing an Adjusted EBITDA Margin in the range of 2.4%-3.6%.&nbsp;</li>
</ul>

WBTN

WEBTOON Entertainment Sees Q4 Revenue Growth On A Constant Currency Basis In The Range Of 10.3%-13.3% ($375M-$385M) Vs $375.92M Est.

Tidewater Sees 2024 Revenue $1.33B-$1.35B vs $1.39B Est.

Innodata (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INOD#NASDAQ">INOD</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.13 by 169.23 percent. The company reported quarterly sales of $52.224 million which beat the analyst consensus estimate of $36.113 million by 44.61 percent. This is a 135.57 percent increase over sales of $22.169 million the same period last year.

INOD

Innodata Q3 2024 Adj. EPS $0.35 Beats $0.13 Estimate, Sales $52.224M Beat $36.113M Estimate

ABNB

Airbnb Sees Q4 2024 Revenue $2.39B-$2.44B Vs $3.717B Est.

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 39.33 percent increase over losses of $(0.89) per share from the same period last year. The company reported quarterly sales of $28.07 million which beat the analyst consensus estimate of $28.02 million by 0.20 percent. This is a 26.41 percent increase over sales of $22.21 million the same period last year.

OUST

Ouster Q3 EPS $(0.54) Beats $(0.57) Estimate, Sales $28.07M Beat $28.02M Estimate

AFRM

Affirm Sees FY25 GMV OF More Than $34B

Accelerate Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.47) by 25.53 percent. This is a 1083.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.975 million which missed the analyst consensus estimate of $3.020 million by 1.49 percent. This is a 9.82 percent decrease over sales of $3.299 million the same period last year.

Earnings Misses

AXDX

Accelerate Diagnostics Q3 2024 GAAP EPS $(0.59) Misses $(0.47) Estimate, Sales $2.975M Miss $3.020M Estimate

Financial Outlook for Full Year 2024
The following tables summarize Getty Images' updated fiscal year 2024 guidance:
<figure class="table"> 
<table>
<tbody>
<tr>
<td>Updated 2024 Guidance</td>
<td>Prior 2024 Guidance</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Revenue</td>
<td>$934 million to $943 million</td>
<td>$924 million to $943 million</td>
</tr>
<tr>
<td>Revenue YoY</td>
<td>1.9% to 2.9%</td>
<td>0.9% to 2.9%</td>
</tr>
<tr>
<td>Revenue YoY, Currency Neutral</td>
<td>1.6% to 2.6%</td>
<td>1.0% to 3.0%</td>
</tr>
<tr>
<td>Adjusted EBITDA</td>
<td>$292 million to $294 million</td>
<td>$290 million to $294 million</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY</td>
<td>(3.1)% to (2.5)%</td>
<td>(3.8)% to (2.5)%</td>
</tr>
<tr>
<td>Adjusted EBITDA YoY, Currency Neutral</td>
<td>(3.4)% to (2.8)%</td>
<td>(3.6)% to (2.3)%</td>
</tr>
</tbody>
</table>
</figure>
 Guidance has been updated to reflect the Company's financial performance year to date and the impact of foreign currency exchange rates on both Revenue and Adjusted EBITDA.

GETY

Getty Images Raises FY24 Revenue From $924M-$943M To $934M-$943M Vs $932.61M Est.

Affirm Sees Q2 Revenue $770M-$810M

CPAY

Corpay Narrows FY24 Total Revenue Outlook From $3.975B - $4.025B To $3.98B - $4.01B (Est $3.989B), Adjusted EPS Forecast From $18.85 - $19.15. To $18.90 - $19.10 (Est $18.96)

Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) narrows FY2024 sales outlook from $269.60 million-281.60 million to $272.60 million-278.60 million.

UPLD

Upland Software Narrows FY2024 Sales Guidance from $269.60M-281.60M to $272.60M-278.60M  VS Est.274.57M

Vinci Partners Inv (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINP#NASDAQ">VINP</a>) reported quarterly earnings of $1.08 per share which beat the analyst consensus estimate of $1.01 by 6.93 percent. The company reported quarterly sales of $112.716 million which beat the analyst consensus estimate of $110.552 million by 1.96 percent. This is a 414.00 percent increase over sales of $21.929 million the same period last year.

VINP

Vinci Partners Inv Q3 2024 Adj. EPS $1.08 Beats $1.01 Estimate, Sales $112.716M Beat $110.552M Estimate

Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) reported quarterly earnings of $0.13 per share which missed the analyst consensus estimate of $0.17 by 23.53 percent. The company reported quarterly sales of $406.019 million which beat the analyst consensus estimate of $392.579 million by 3.42 percent. This is a 16.48 percent increase over sales of $348.571 million the same period last year.

GDOT

Green Dot Q3 2024 Adj. EPS $0.13 Misses $0.17 Estimate, Sales $406.019M Beat $392.579M Estimate

Clearfield (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLFD#NASDAQ">CLFD</a>) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.19) by 68.42 percent. This is a 135.29 percent decrease over earnings of $0.17 per share from the same period last year. The company reported quarterly sales of $46.77 million which beat the analyst consensus estimate of $41.95 million by 11.49 percent. This is a 5.86 percent decrease over sales of $49.69 million the same period last year.

CLFD

Clearfield Q4 EPS $(0.06) Beats $(0.19) Estimate, Sales $46.77M Beat $41.95M Estimate

Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) sees Q4 sales of $29.000 million-31.000 million vs $29.93 million estimate.

Ouster Sees Q4 Sales $29.000M-31.000M vs $29.93M Est

AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is looking for Q4 Adj EPS of $0.18-0.19 vs $0.01 analyst estimate. sees sales of $9.700 million-9.800 million vs $9.47 million estimate.

AEYE

AudioEye Sees Q4 Adj EPS $0.18-0.19 vs $0.01 Est; Sees Sales $9.700M-9.800M vs $9.47M Est

Business Outlook
Gary Yu further commented, "For the fourth quarter of 2024, we expect revenue to be approximately $337 million, plus or minus 3 percent, representing a 3.7% sequential decrease at the mid-point, slightly better than typical seasonality. GAAP gross margin is expected to be 33.0 percent, plus or minus 1 percent. Non-GAAP operating expenses, which are GAAP operating expenses adjusted for amortization of acquisition-related intangible assets, are expected to be approximately 28.0 percent of revenue, plus or minus 1 percent. We expect net interest income to be approximately $2.5 million. Our income tax rate is expected to be 18.0 percent, plus or minus 3 percent, and shares used to calculate diluted EPS for the fourth quarter are anticipated to be approximately 46.7 million."
Amortization of acquisition-related intangible assets of $3.1 million, after tax, for previous acquisitions is not included in these non-GAAP estimates.

DIOD

Diodes Inc. Sees Q4 Revenue ~$337M +/- 3% Vs $351.74M Est.

AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) raises FY2024 Adj EPS guidance from $0.51-0.53 to $0.54-0.55 vs $(0.13) analyst estimate. Raises FY2024 sales outlook from $35.15 million-35.25 million to $35.20 million-35.30 million vs $34.93 million estimate.

AudioEye Raises FY2024 Adj EPS Guidance from $0.51-0.53 to $0.54-0.55 vs $(0.13) Est; Raises FY2024 Sales Guidance from $35.15M-35.25M to $35.20M-35.30M vs $34.93M Est

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

RIVN

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Management

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Markets

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

ImmuCell

MiNK Therapeutics

Longeveron

Lantern Pharma

Lumos Pharma

Marker Therapeutics

NextCure

Ocean Biomedical

SAB Biotherapeutics

Surrozen

vTv Therapeutics Inc. - Class A Common Stock

Comments

Celularity

空売り

Celularity (NASDAQ:CELU) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル